Related Experiment Video

Updated: Jun 17, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Predictive toxicology approaches for small molecule oncology drugs

T Maziasz, V J Kadambi, L Silverman

    Toxicologic Pathology
    |January 16, 2010
    PubMed

    Insights

    Developing effective cancer chemotherapies is critical due to high mortality rates. Optimized nonclinical toxicology testing strategies are essential for accelerating the approval of novel oncology drug candidates.

    Area of Science:

    • Oncology
    • Toxicology
    • Drug Development

    Background:

    • Significant unmet medical need exists for effective cancer chemotherapies, with over 560,000 deaths in the US in 2009.
    • Metastatic cancer necessitates a distinct drug development paradigm compared to less severe diseases.
    • Many novel oncology drug candidates target cancer-specific pathways, but may present unique toxicological challenges.

    Purpose of the Study:

    • To outline a successful nonclinical toxicology testing strategy for oncology drug candidates.
    • To address the challenges in decision-making for novel chemotherapeutics with potential off-target toxicities.
    • To support the acceleration of oncology drug development and approval processes.

    Main Methods:

    • Review of current regulatory paradigms for nonclinical oncology testing.
    • Analysis of toxicological profiles associated with novel targeted cancer therapies.
    • Strategies for compressing development timelines while ensuring regulatory compliance.

    Main Results:

    • The U.S. Food and Drug Administration has established an oncology-specific framework for nonclinical testing.
    • Accelerated development strategies aim to expedite the availability of promising cancer therapies.
    • Effective toxicology testing is crucial for reducing high attrition rates in oncology drug development.

    Conclusions:

    • Optimized toxicology testing strategies are vital for regulatory success and reducing attrition rates.
    • A robust nonclinical testing approach is fundamental for bringing effective oncology treatments to patients faster.
    • Addressing unique toxicological profiles of novel agents is key to successful oncology drug development.

    Related Concept Videos

    Toxicity Testing in Animals01:23

    Toxicity Testing in Animals

    Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
    Toxicokinetics: Overview01:21

    Toxicokinetics: Overview

    Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
    Drug Discovery: Overview01:26

    Drug Discovery: Overview

    Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
    Drug Toxicity: Dose-Dependent Reactions01:24

    Drug Toxicity: Dose-Dependent Reactions

    Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...